UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended October 2, 2011
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES x NO o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES x NO o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer x
Accelerated filer o
Non-accelerated filer o
Smaller reporting company o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES o NO x
At November 7, 2011, 7,686,966,786 shares of the issuer s voting common stock were outstanding.
FORM 10-Q
For the Quarter Ended
October 2, 2011
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and nine months ended October 2, 2011 and October 3, 2010
Condensed Consolidated Balance Sheets as of October 2, 2011 and December 31, 2010
Condensed Consolidated Statements of Cash Flows for the nine months ended October 2, 2011 and October 3, 2010
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
40
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
41
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
79
Item 4.
Controls and Procedures
79
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
79
Item 1A.
Risk Factors
79
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
80
Item 3.
Defaults Upon Senior Securities
80
Item 5.
Other Information
80
Item 6.
Exhibits
80
Signature
81
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Nine Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
Oct. 2,
2011
Oct. 3,
2010
Oct. 2,
2011
Oct. 3,
2010
Revenues
17,193
15,995
50,679
49,703
Costs and expenses:
Cost of sales(a)
3,679
3,790
11,177
11,676
Selling, informational and administrative expenses(a)
4,621
4,599
14,097
13,776
Research and development expenses(a)
2,188
2,188
6,516
6,590
Amortization of intangible assets
1,397
1,156
4,168
3,972
Acquisition-related in-process research and development
charges
74
Restructuring charges and certain acquisition-related costs
1,101
499
2,474
2,090
Other deductions net
538
2,349
1,778
3,036
Income from continuing operations before provision for taxes on income
3,669
1,414
10,469
8,489
Provision for taxes on income
1,235
558
3,223
3,165
Income from continuing operations
2,434
856
7,246
5,324
Discontinued operations:
(Loss)/income from discontinued operations net of tax
(13
26
39
76
Gain/(loss) on sale of discontinued operations net of tax
1,328
(11
1,316
(9
Discontinued operations net of tax
1,315
15
1,355
67
Net income before allocation to noncontrolling interests
3,749
871
8,601
5,391
Less: net income attributable to noncontrolling interests
11
31
24
Net income attributable to Pfizer Inc.
3,738
866
8,570
5,367
Earnings per share basic:(b)
Income from continuing operations attributable to Pfizer Inc.
common shareholders
0.31
0.11
0.92
0.66
Discontinued operations net of tax
0.17
0.17
0.01
Net income attributable to Pfizer Inc. common shareholders
0.48
0.11
1.09
0.67
Earnings per share diluted:(b)
Income from continuing operations attributable to Pfizer Inc.
common shareholders
0.31
0.11
0.91
0.66
Discontinued operations net of tax
0.17
0.17
0.01
Net income attributable to Pfizer Inc. common shareholders
0.48
0.11
1.08
0.66
Weighted-average shares used to calculate earnings per common share:
Basic
7,770
8,027
7,877
8,045
Diluted
7,810
8,057
7,925
8,079
Cash dividends paid per common share
0.20
0.18
0.60
0.54
(a)
Exclusive of amortization of intangible assets, except as disclosed in Note 11B. Goodwill and Other Intangible Assets: Other Intangible Assets.
(b)
EPS amounts may not add due to rounding.
See accompanying Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(millions of dollars)
Oct. 2,
2011
Dec. 31,
2010
(Unaudited)
Assets
Cash and cash equivalents
3,706
1,735
Short-term investments
25,257
26,277
Accounts receivable, less allowance for doubtful accounts
15,749
14,426
Short-term loans
184
467
Inventories
8,426
8,275
Taxes and other current assets
9,288
8,394
Assets of discontinued operations and other assets held for sale
122
1,439
Total current assets
62,732
61,013
Long-term investments and loans
9,468
9,747
Property, plant and equipment, less accumulated depreciation
17,721
18,645
Goodwill
45,409
43,928
Identifiable intangible assets, less accumulated amortization
55,597
57,555
Taxes and other noncurrent assets
5,205
4,126
Total assets
196,132
195,014
Liabilities and Shareholders Equity
Short-term borrowings, including current portion of long-term debt
5,637
5,603
Accounts payable
3,765
3,994
Dividends payable
1,601
Income taxes payable
2,215
951
Accrued compensation and related items
1,999
2,080
Other current liabilities
14,240
14,256
Liabilities of discontinued operations
151
Total current liabilities
27,856
28,636
Long-term debt
35,399
38,410
Pension benefit obligations
5,734
6,194
Postretirement benefit obligations
3,059
3,035
Noncurrent deferred tax liabilities
20,415
18,628
Other taxes payable
6,900
6,245
Other noncurrent liabilities
6,239
5,601
Total liabilities
105,602
106,749
Commitments and Contingencies
Preferred stock
46
52
Common stock
445
444
Additional paid-in capital
71,235
70,760
Employee benefit trusts
(3
(7
Treasury stock
(28,586
(22,712
Retained earnings
48,121
42,716
Accumulated other comprehensive loss
(1,211
(3,440
Total Pfizer Inc. shareholders equity
90,047
87,813
Equity attributable to noncontrolling interests
483
452
Total shareholders equity
90,530
88,265
Total liabilities and shareholders equity
196,132
195,014
See accompanying Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Nine Months Ended
(millions of dollars)
Oct. 2,
2011
Oct. 3,
2010
Operating Activities:
Net income before allocation to noncontrolling interests
8,601
5,391
Adjustments to reconcile net income before allocation to noncontrolling interests to net
cash provided by operating activities:
Depreciation and amortization
6,656
6,493
Share-based compensation expense
347
351
Asset write-offs and impairment charges
773
2,956
Acquisition-related in-process research and development charges
74
(Gain)/loss on sale of discontinued operations
(1,683
Deferred taxes from continuing operations
693
1,277
Other deferred taxes
175
Other non-cash adjustments
26
(135
Benefit plan contributions in excess of expense
(283
(706
Other changes in assets and liabilities, net of acquisitions and divestitures
(326
(10,514
Net cash provided by operating activities
14,979
5,196
Investing Activities:
Purchases of property, plant and equipment
(1,062
(966
Purchases of short-term investments
(13,456
(5,018
Proceeds from redemptions and sales of short-term investments net
17,458
9,493
Purchases of long-term investments
(3,446
(2,674
Proceeds from redemptions and sales of long-term investments
2,001
3,822
Acquisitions, net of cash acquired
(3,188
Proceeds from sale of business
2,376
Other investing activities
618
496
Net cash provided by investing activities
1,301
5,153
Financing Activities:
Increase in short-term borrowings
9,613
4,686
Principal payments on short-term borrowings net
(10,069
(9,265
Principal payments on long-term debt
(3,486
(4
Purchases of common stock
(5,789
(1,000
Cash dividends paid
(4,710
(4,544
Other financing activities
84
32
Net cash used in financing activities
(14,357
(10,095
Effect of exchange-rate changes on cash and cash equivalents
48
(56
Net increase in cash and cash equivalents
1,971
198
Cash and cash equivalents at beginning of period
1,735
1,978
Cash and cash equivalents at end of period
3,706
2,176
Supplemental Cash Flow Information:
Cash paid during the period for:
Income taxes
1,539
11,519
Interest
1,872
2,039
See accompanying Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation
We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month and nine-month periods ended August 28, 2011, and August 29, 2010. We have made certain reclassification adjustments to conform prior-period amounts to the current presentation, primarily related to discontinued operations (see Note 4. Discontinued Operations) and segment reporting (see Note 15. Segment, Product and Geographic Area Information).
On January 31, 2011, we completed the tender offer for all of the outstanding shares of common stock of King Pharmaceuticals, Inc. (King) and acquired approximately 92.5% of the outstanding shares for approximately $3.3 billion in cash. On February 28, 2011, we acquired the remaining outstanding shares of King for approximately $300 million in cash (for additional information, see Note 3. Acquisition of King Pharmaceuticals, Inc.). Commencing from January 31, 2011, our financial statements include the assets, liabilities, operating results and cash flows of King. Therefore, in accordance with our domestic and international reporting periods, our condensed consolidated financial statements for the nine months ended October 2, 2011 reflect approximately eight months of King s U.S. operations and approximately seven months of King s international operations.
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements included in this document. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2010.
Note 2. Adoption of New Accounting Standards
The provisions of the following new accounting standards were adopted as of January 1, 2011 and did not have a significant impact on our condensed consolidated financial statements:
New guidelines that address the recognition and presentation of the annual fee paid by pharmaceutical companies beginning on January 1, 2011 to the U.S. Treasury as a result of U.S. Healthcare Legislation. As a result of adopting this new standard, we are recording the annual fee ratably throughout the year in the Selling, informational and administrative expenses line item in our condensed consolidated statement of income.
An amendment to the guidelines that address the accounting for multiple-deliverable arrangements to enable companies to account for certain products or services separately rather than as a combined unit.
Note 3. Acquisition of King Pharmaceuticals, Inc.
On January 31, 2011 (the acquisition date), we completed the tender offer for all of the outstanding shares of common stock of King at a purchase price of $14.25 per share in cash and acquired approximately 92.5% of the outstanding shares. On February 28, 2011, we acquired all of the remaining shares of King for $14.25 per share in cash. As a result, the total fair value of consideration transferred for King was approximately $3.6 billion in cash ($3.2 billion, net of cash acquired).
King s principal businesses consist of a prescription pharmaceutical business focused on delivering new formulations of pain treatments designed to discourage common methods of misuse and abuse; the Meridian auto-injector business for emergency drug delivery, which develops and manufactures the EpiPen; an established products portfolio; and an animal health business that offers a variety of feed-additive products for a wide range of species.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
(millions of dollars)
Amounts
Recognized as of
Acquisition Date
(Provisional)
Working capital, excluding inventories
174
Inventories
340
Property, plant and equipment
412
Identifiable intangible assets, excluding in-process research and development
1,822
In-process research and development
312
Net tax accounts
(389
All other long-term assets and liabilities, net
101
Total identifiable net assets
2,772
Goodwill
783
Net assets acquired/total consideration transferred
3,555
As of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was $200 million, virtually all of which was expected to be collected.
Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the acquisition of King includes the following:
the expected synergies and other benefits that we believe will result from combining the operations of King with the operations of Pfizer;
any intangible assets that do not qualify for separate recognition, as well as future, yet unidentified projects and products; and
the value of the going-concern element of King s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the net assets separately).
Goodwill is not amortized and is not deductible for tax purposes. While the allocation of goodwill among reporting units is not complete, we expect that substantially all of the goodwill will be related to our biopharmaceutical reporting units (see Note 11. Goodwill and Other Intangible Assets for additional information).
The assets and liabilities arising from contingencies recognized at acquisition date, some of which are subject to change, are not significant to Pfizer s condensed consolidated financial statements.
The recorded amounts are provisional and subject to change. Specifically, the following items are subject to change:
Amounts for intangibles and inventory, pending finalization of valuation efforts;
Amounts for income tax assets, receivables and liabilities pending the filing of King s pre-acquisition tax returns and the receipt of information from taxing authorities, which may change certain estimates and assumptions used; and
The allocation of goodwill among reporting units.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Revenues from King are included in Pfizer s condensed consolidated statements of income from the acquisition date, January 31, 2011, through Pfizer s third-quarter 2011 domestic and international quarter-ends and were $357 million for the third quarter of 2011 and $938 million in the first nine months of 2011. We are no longer able to provide the results of operations attributable to King as those operations have now been substantially integrated into the larger Pfizer operation.
The following table presents supplemental pro forma information as if the acquisition of King had occurred on January 1, 2010:
Pro Forma Consolidated Results
Three Months
Ended
Nine Months Ended
(millions of dollars, except per share data)
Oct. 3,
2010
Oct. 2,
2011
Oct. 3,
2010
Revenues
16,335
50,788
50,749
Net income attributable to Pfizer Inc. common shareholders
854
8,769
5,163
Diluted earnings per share attributable to Pfizer Inc. common shareholders
0.11
1.11
0.64
The unaudited pro forma consolidated results do not purport to project the future results of operations of the combined company nor do they reflect the expected realization of any cost savings associated with the acquisition. The unaudited pro forma consolidated results reflect the historical financial information of Pfizer and King, adjusted for the following pre-tax amounts:
Elimination of King s historical intangible asset amortization expense (approximately $18 million in the third quarter of 2010, $6 million in the first nine months of 2011 and $98 million in the first nine months of 2010).
Additional amortization expense (approximately $48 million in the third quarter of 2010, $15 million in the first nine months of 2011 and $136 million in the first nine months of 2010) related to the fair value of identifiable intangible assets acquired.
Additional depreciation expense (approximately $9 million in the third quarter of 2010, $3 million in the first nine months of 2011 and $26 million in the first nine months of 2010) related to the fair value adjustment to property, plant and equipment acquired.
Adjustment related to the fair value adjustments to acquisition-date inventory estimated to have been sold (addition of $33 million charge in the third quarter of 2010, elimination of $146 million charge in the first nine months of 2011 and addition of $146 million charge in the first nine months of 2010).
Adjustment for acquisition-related costs directly attributable to the acquisition (addition of $11 million of charges in the third quarter of 2010, elimination of $205 million of charges in the first nine months of 2011 and addition of $205 million of charges in the first nine months of 2010, reflecting charges incurred by both King and Pfizer).
Note 4. Discontinued Operations
We evaluate our businesses and product lines periodically for their strategic fit within our operations. In 2011, we decided to sell our Capsugel business. In connection with the decision to sell this business, for all periods presented, the operating results associated with this business have been reclassified into Discontinued operations net of tax in the Condensed Consolidated Statements of Income, and the assets and liabilities associated with this business have been reclassified into Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in the Condensed Consolidated Balance Sheets.
On April 4, 2011, we announced that we had entered into an agreement to sell Capsugel to an affiliate of Kohlberg Kravis Roberts & Co. L.P. for approximately $2.4 billion in cash. The transaction closed on August 1, 2011.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The following amounts, substantially all of which relate to our Capsugel business, have been segregated from continuing operations and included in Discontinued operations net of tax in our Condensed Consolidated Statements of Income:
Three Months Ended
Nine Months Ended
(millions of dollars)
Oct. 2,
2011
Oct. 3,
2010
Oct. 2,
2011
Oct. 3,
2010
Revenues
116
176
507
545
Pre-tax (loss)/income from discontinued operations
(7
29
78
106
Provision for taxes on income(a)
39
30
(Loss)/income from discontinued operations net of tax
(13
26
39
76
Pre-tax gain/(loss) on sale of discontinued operations
1,695
(12
1,683
(9
Provision/(benefit) for taxes on income(b)
367
(1
367
Discontinued operations net of tax
1,315
15
1,355
67
(a)
Includes a deferred tax expense of $13 million for the first nine months of 2011.
(b)
Includes a deferred tax expense of $162 million for the third quarter and first nine months of 2011.
The following assets and liabilities, which in 2010 include the assets and liabilities related to our Capsugel business, have been segregated and included in Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in our Condensed Consolidated Balance Sheets:
(millions of dollars)
Oct. 2,
2011
Dec. 31,
2010
Accounts receivable
186
Inventories
130
Taxes and other current assets
12
47
Property, plant and equipment
110
1,009
Goodwill
19
Identifiable intangible assets
Taxes and other noncurrent assets
45
Assets of discontinued operations and other assets held for sale
122
1,439
Current liabilities
124
Other liabilities
27
Liabilities of discontinued operations
151
The net cash flows of our discontinued operations for each of the categories of operating, investing and financing activities were not significant for the first nine months of 2011 or 2010.
Note 5. Costs Associated with Cost-Reduction and Productivity Initiatives and Acquisition Activity
We incur significant costs in connection with acquiring businesses and restructuring and integrating acquired businesses and in connection with our global cost-reduction and productivity initiatives. For example:
for our cost-reduction and productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems; and
for our acquisition activity, we typically incur costs that can include transaction costs, integration costs (such as expenditures for consulting and the integration of systems and processes) and restructuring charges, related to employees, assets and activities that will not continue in the combined company.
On February 1, 2011, we announced a new research and productivity initiative to accelerate our strategies to improve innovation and overall productivity in R&D by prioritizing areas with the greatest scientific and commercial promise, utilizing appropriate risk/return profiles and focusing on areas with the highest potential to deliver value in the near term and over time.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
We incurred the following costs in connection with our cost-reduction and productivity initiatives and acquisition activity, such as King (acquired in 2011) and Wyeth (acquired in 2009):
Three Months Ended
Nine Months Ended
(millions of dollars)
Oct. 2,
2011
Oct. 3,
2010
Oct. 2,
2011
Oct. 3,
2010
Transaction costs(a)
28
13
Integration costs(b)
187
231
567
650
Restructuring charges(c):
Employee termination costs
770
27
1,626
603
Asset impairments
99
174
157
677
Other
40
67
96
147
Restructuring charges and certain acquisition-related costs
1,101
499
2,474
2,090
Additional depreciation asset restructuring(d):
Cost of sales
68
241
411
367
Selling, informational and administrative expenses
39
27
69
190
Research and development expenses
146
25
378
45
Total additional depreciation asset restructuring
253
293
858
602
Implementation costs(e):
Selling, informational and administrative expenses
11
11
Research and development expenses
28
Total implementation costs
19
39
Total costs associated with cost-reduction and productivity initiatives and
acquisition activity
1,373
792
3,371
2,692
(a)
Transaction costs represent external costs directly related to acquired businesses and primarily include expenditures for banking, legal, accounting and other similar services.
(b)
Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes.
(c)
From the beginning of our cost-reduction and transformation initiatives in 2005 through October 2, 2011, Employee termination costs represent the expected reduction of the workforce by approximately 57,800 employees, mainly in manufacturing and sales and research, of which approximately 41,000 employees have been terminated as of October 2, 2011. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments primarily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities.
The restructuring charges in 2011 are associated with the following:
For the three months ended October 2, 2011, Primary Care operating segment ($473 million), Specialty Care and Oncology operating segment ($186 million), Established Products and Emerging Markets operating segment ($65 million), Animal Health and Consumer Healthcare operating segment ($30 million), Nutrition operating segment ($2 million), research and development operations ($47 million income), manufacturing operations ($47 million) and Corporate ($153 million).
For the nine months ended October 2, 2011, Primary Care operating segment ($606 million), Specialty Care and Oncology operating segment ($228 million), Established Products and Emerging Markets operating segment ($80 million), Animal Health and Consumer Healthcare operating segment ($44 million), Nutrition operating segment ($4 million), research and development operations ($426 million), manufacturing operations ($203 million) and Corporate ($288 million).
The restructuring charges in 2010 are associated with the following:
For the three months ended October 3, 2010, Primary Care operating segment ($14 million), Specialty Care and Oncology operating segment ($53 million), Established Products and Emerging Markets operating segment ($14 million), Nutrition operating segment ($1 million), research and development operations ($17 million), manufacturing operations ($161 million) and Corporate ($8 million).
For the nine months ended October 3, 2010, Primary Care operating segment ($1 million), Specialty Care and Oncology operating segment ($99 million), Established Products and Emerging Markets operating segment ($23 million), Animal Health and Consumer Healthcare operating segment ($33 million), Nutrition operating segment ($12 million income), research and development operations ($239 million), manufacturing operations ($970 million) and Corporate ($74 million).
(d)
Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(e)
Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction and productivity initiatives.
10
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The components of restructuring charges associated with all of our cost-reduction and productivity initiatives and acquisition activity follow:
Costs Incurred
Activity
Accrual
(millions of dollars)
2005-2011
Through
Oct. 2,
2011(a)
As of
Oct. 2,
2011(b)
Employee termination costs
10,437
7,720
2,717
Asset impairments
2,465
2,465
Other
996
889
107
Total restructuring charges
13,898
11,074
2,824
(a)
Includes adjustments for foreign currency translation.
(b)
Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($1.1 billion).
Note 6. Other (Income)/Deductions Net
The following table sets forth details related to amounts recorded in Other deductions net: